For following the competition: what moved in each program, several studies read as one move.
- TEAD Inhibitor VT3989
- EB-MF-CAR-NK-01
- TYK-01054
- + 3 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Mesothelioma, Malignant to watchlistEvery Monday by email · turn it off any timePro · free during the beta